Dompé Email Format

Pharmaceutical ManufacturingLombardy, Italy1001-5000 Employees

Dompé is a private, family-owned biopharmaceutical company with more than 130 years of independent history, focused on redefining treatments for ophthalmic, neurological, and pain-related conditions through breakthrough science.

As the first company to unlock the therapeutic potential of nerve growth factor (NGF), Dompé is advancing first-in-class, disease-modifying therapies that target the underlying causes of nerve damage rather than symptoms alone. Building on Nobel Prize-winning science, our work has already led to the approval of the first topical biologic in ophthalmology for a rare neurotrophic eye disease, and continues to expand into high-unmet-need areas across eye, brain, and pain indications.  

Our research and development model combines scientific rigor with agility. Our curiosity-driven R&D team follows the science where it leads - developing innovative biologics, advancing multiple clinical programs, and exploring new delivery platforms - to address complex and hard-to-treat diseases. 

Independence is central to who we are. It enables long-term thinking, sustained investment in innovation, and the ability to integrate research, manufacturing, and commercialization with the discipline of an established pharmaceutical company and the speed of a biotech.  

Beyond science, Dompé is deeply committed to patients, access to care, and the next generation of scientific leaders—through patient support programs and long-standing investments in education and talent development.

Our mission is clear: to bring the full potential of NGF and other breakthrough molecules to patients, and in doing so, transform how diseases of the nervous system are treated.

Sign up for free to view info

Company overview Employee directory